(1 - 13 from 15
)
AstraZeneca pill slows thyroid cancer progression - Reuters
www.reuters.com
Peter Langmuir, executive director of medical science, told Reuters that AstraZeneca would use the data to file for regulatory approval in MTC ...
www.pharmatimes.com › news › astrazeneca_thyroid_cancer_drug_impr...AstraZeneca thyroid cancer drug impresses in Phase III ...
www.pharmatimes.com
Peter Langmuir, executive director of medical science at the Anglo-Swedish drugmaker, said that patients with advanced MTC “currently have ...
AstraZeneca Says Thyroid Cancer Drug Vandetanib Meets Primary...
www.rttnews.com
AstraZeneca Says Thyroid Cancer Drug Vandetanib Meets Primary ... Peter Langmuir, M.D. Executive Director, Medical-Science, AstraZeneca said, "Patients with advanced medullary ...
Vandetanib Phase II Trial Shows Significant Improvement Of...
www.science20.com
Vandetanib Phase II Trial Shows Significant Improvement Of Progression Free ... treatment with radioactive iodine, said Peter Langmuir, M.D. Executive Director, Medical ...
sorted by relevance / date